Abstract

Venetoclax is an inhibitor of the anti-apoptotic B-cell lymphoma-2 (BCL-2) protein that has revolutionised the management of acute myeloid leukaemia in the past 5 years. Venetoclax in combination with azacitidine has become the new standard of care for the majority of patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy due to age, fitness, or comorbidities.1 Venetoclax has improved outcomes for this patient population and represents a valuable new treatment option in this setting.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call